RxDoctor Payments Data

Jacqueline Rodriguez

Women's Health · Huntington Park, CANPI 1598831505

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 45.0% of the total. Among women's health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,498in general payments, 2019–2025

Across 118 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Boehringer Ingelheim$233
  • Amgen$226
  • AstraZeneca$144
  • Astellas Pharma US Inc$135
  • Xeris Pharmaceuticals, Inc.$116
  • plus $520 from 13 others

What the payments were for

  • Food & beverage$2,43297%
  • Education$663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,498 in reported general payments places this provider in the 90th percentile of 480 women's health providers in California.

See all women's health providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$44,364
OzempicSemaglutide41$38,337
TradjentaLinagliptin30$24,539
RybelsusSemaglutide15$18,242
JanuviaSitagliptin Phosphate23$18,239
FarxigaDapagliflozin Propanediol23$15,744
EliquisApixaban12$7,801
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$7,592
Atorvastatin Calcium413$4,839
Fenofibrate146$4,314
Febuxostat20$3,797
Celecoxib32$3,468
Humalog Kwikpen U-100Insulin Lispro14$2,085
Glipizide ErGlipizide89$2,050
Levothyroxine Sodium128$2,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$233$68,90376 claims
Novo NordiskOzempic, Rybelsus$1,124$56,57956 claims
MerckJanuvia$21$18,23923 claims
AstraZenecaFarxiga$144$15,74423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 480 women's health providers in California.

Other women's health in Huntington Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →